Kristen Berrebi

Associate Professor, Clinical Medical Director of Pediatric Dermatology

Children's Hospital Colorado
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (9)

Year:

2026

Year:

2026

PURPOSE The purpose of this study was to develop recommendations for the diagnostic evaluation and surgical management of cutaneous melanoma (CM) and atypical Spitz tumors (AST) and non-Spitz melanocytic tumors (melanocytomas) in pediatric (age 0-10 years) and adolescent (age 11-18 years) patients. METHODS A Children's Oncology Group–led panel with external, multidisciplinary CM specialists convened to develop recommendations on the basis of available data and expertise. RESULTS Thirty-three experts from multiple specialties (cutaneous/medical/surgical oncology, dermatology, and dermatopathology) established recommendations with supporting data from 87 peer-reviewed publications. RECOMMENDATIONS (1) Excisional biopsies with 1-3 mm margins should be performed when feasible for clinically suspicious melanocytic neoplasms. (2) Definitive surgical treatment for CM, including wide local excision and sentinel lymph node biopsy (SLNB), should follow National Comprehensive Cancer Network Guidelines in the absence of data from pediatric-specific surgery trials and/or cohort studies. (3) Accurate classification of ASTs as benign or malignant is more likely with immunohistochemistry and next-generation sequencing. (4) It may not be possible to classify some ASTs as likely/definitively benign or malignant after clinicopathologic and/or molecular correlation, and these Spitz tumors of uncertain malignant potential should be excised with 5 mm margins. (5) ASTs favored to be benign should be excised with 1- to 3-mm margins if transected on biopsy. (6) Re-excision is not necessary if the AST does not extend to the biopsy margin(s) when complete/excisional biopsy was performed. (7) SLNB should not be performed for Spitz tumors unless a diagnosis of CM is favored on clinicopathologic evaluation. (8) Non-Spitz melanocytomas have a presumed increased risk for progression to CM and should be excised with 1- to 3-mm margins if transected on biopsy. (9) Re-excision of non-Spitz melanocytomas is not necessary if the lesion is completely excised on biopsy.

Year:

2025

Alopecia areata (AA) is an autoimmune non‐scarring hair loss that arises in genetically susceptible individuals, potentially in combination with environmental triggers or inciting events, of which the exact mechanism is not yet fully understood. Genome wide association studies have demonstrated an association between AA and variants in HLA haplotypes on chromosome 6 which correlate with other autoimmune conditions as well as other gene variants. Familial and twin studies also confer additional evidence to a genetic component. AA pathogenesis relies on immune privilege collapse at the hair follicle (HF) bulb in the anagen hair cycle phase. Immune privilege collapse is associated with upregulation of IFN‐γ, ultimately activating JAK‐STAT pathway resulting in upregulation of MHC class I and II in the HF and subjecting it to attack by NKG2D + CD8 T cells. The complex interplay between pro‐inflammatory cytokines such as IFN‐γ, IL‐2, IL‐15 and their use of JAK‐STAT signaling are important in perpetuation of AA.

Year:

2025

As more neonatal centers are caring for premature infants at 21–23 weeks’ gestational age (GA), a growing need for improved practices related to routine skin care exists. Approach to skin care in this GA is challenging because the skin barrier is not completely formed at this developmental stage, leading to an increased risk of insensible water loss; increased sodium and nutritional requirement; and greater susceptibility to injury, infection, and temperature instability. Effective skin care in this population requires a proactive, standardized, multidisciplinary approach. In this review, we describe an expert and experience-based guide for skin care in this population with a focus on infection prevention, fluid and nutrition management, avoidance of injury, and routine skin care.

Year:

2025

Bullous pemphigoid (BP) is an autoimmune blistering disease primarily affecting the elderly, whereas cases of juvenile BP are rare. Both types of BP are typically mediated by autoantibodies targeting the NC16A region of BP180; however, a small subset of adult patient sera react to other regions of the protein. The incidence of a similar occurrence in juvenile BP is unknown. This case of juvenile BP with a negative BP180 ELISA highlights diagnostic pitfalls that can lead to a delay in the correct diagnosis in the pediatric population.

Year:

2024

Protoporphyria is a subtype of porphyria characterized primarily by painful phototoxic skin reactions after light exposure at specific wavelengths. Historically, phototherapy is not contraindicated in patients with protoporphyria since there have not been any reports of phototoxic reactions. However, patients with protoporphyria are advised to avoid direct sunlight. In this case report, we describe a neonate not known to have X-linked protoporphyria who received phototherapy for 1 to 2 hours. Within hours after initiation of phototherapy, this neonate developed a life-threatening reaction consisting of rash over the distribution of phototherapy, acute liver failure with coagulopathy, diffuse hypotonia with diaphragmatic failure, and subsequent acute respiratory failure that required mechanical ventilation. As in this case, patients with protoporphyria-related acute liver failure can have signs and symptoms similar to that of an acute hepatic porphyria attack. Neither neonatal reactions to phototherapy nor liver failure temporally associated with phototherapy have been reported in patients with X-linked protoporphyria. Early recognition of this entity is crucial in light of potential life-threatening complications. Therefore, providers must react quickly when neonates have abnormal reactions to phototherapy and consider protoporphyria in the differential diagnosis.

Year:

2024

Year:

2023

Year:

2023

Collaborators (13)

Bryan Brindeiro

Clinical Assistant Professor

The University of Iowa

UNITED STATES
View details

Susan M. Swetter

-

UNITED STATES
View details

Armita Bahrami

Emory University

UNITED STATES
View details

Alberto Pappo

Member

St. Jude Children's Research Hospital

UNITED STATES
View details

Katherine Keech

Clinical Associate Professor

The University of Iowa

UNITED STATES
View details

Michael Sargen

Lasker Clinical Research Scholar

National Cancer Institute

UNITED STATES
View details

Amy Stanford

Clinical Assistant Professor of Pediatrics

The University of Iowa University College

UNITED STATES
View details

Jennifer Bermick

Associate Professor

The University of Iowa Stead Family Children's Hospital

UNITED STATES
View details

Stephen Hays

Clinical Professor

The University of Iowa

UNITED STATES
View details

Nathan Blair

Clinical Assistant Professor

The University of Iowa

UNITED STATES
View details

Martha Herbst

Clinical Associate Professor

The University of Iowa

UNITED STATES
View details

Janet Fairley

Professor and Chair

Iowa State University

UNITED STATES
View details

Ali Jabbari

Professor

Iowa State University

UNITED STATES
View details